Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
365.8 USD | +0.01% | +1.54% | +3.44% |
Apr. 25 | Everest Medicines' Loss Widens in 2023 | MT |
Apr. 24 | India inspects facilities of spice makers MDH and Everest, regulator says | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company returns high margins, thereby supporting business profitability.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- Sales forecast by analysts have been recently revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Reinsurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.44% | 17.83B | B- | ||
+12.82% | 61.55B | A- | ||
+5.27% | 29.91B | B+ | ||
+12.04% | 11.59B | C | ||
+2.50% | 2.07B | - | C+ | |
-6.02% | 1.57B | - | ||
+6.40% | 985M | - | ||
-6.91% | 647M | C- | ||
+39.78% | 634M | C+ | ||
+6.39% | 435M | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EG Stock
- Ratings Everest Group, Ltd.